
Zylox-Tonbridge Medical Technology Co Ltd
HKEX:2190

Zylox-Tonbridge Medical Technology Co Ltd
Revenue
Zylox-Tonbridge Medical Technology Co Ltd
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
![]() |
Zylox-Tonbridge Medical Technology Co Ltd
HKEX:2190
|
Revenue
ÂĄ527.8m
|
CAGR 3-Years
167%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
A
|
APT Medical Inc
SSE:688617
|
Revenue
ÂĄ1.7B
|
CAGR 3-Years
51%
|
CAGR 5-Years
47%
|
CAGR 10-Years
N/A
|
|
J
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SZSE:002223
|
Revenue
ÂĄ7.3B
|
CAGR 3-Years
1%
|
CAGR 5-Years
10%
|
CAGR 10-Years
16%
|
|
![]() |
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
Revenue
ÂĄ37.1B
|
CAGR 3-Years
15%
|
CAGR 5-Years
19%
|
CAGR 10-Years
N/A
|
|
L
|
Lepu Medical Technology Beijing Co Ltd
SZSE:300003
|
Revenue
ÂĄ6.5B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
15%
|
|
![]() |
Shanghai United Imaging Healthcare Co Ltd
SSE:688271
|
Revenue
ÂĄ11.4B
|
CAGR 3-Years
26%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
Zylox-Tonbridge Medical Technology Co Ltd
Glance View
Zylox-Tonbridge Medical Technology Co., Ltd. operates as a medical devices company. The company is headquartered in Hangzhou, Zhejiang and currently employs 487 full-time employees. The company went IPO on 2021-07-05. The firm's main products include Thrombite Clot Retriever Device (Thrombite CRD) and Ultrafree Drug Coated PTA Balloon Catheter (Ultrafree DCB). The firm's products are sold to domestic and foreign markets.

See Also
What is Zylox-Tonbridge Medical Technology Co Ltd's Revenue?
Revenue
527.8m
CNY
Based on the financial report for Dec 31, 2023, Zylox-Tonbridge Medical Technology Co Ltd's Revenue amounts to 527.8m CNY.
What is Zylox-Tonbridge Medical Technology Co Ltd's Revenue growth rate?
Revenue CAGR 3Y
167%
Over the last year, the Revenue growth was 58%. The average annual Revenue growth rates for Zylox-Tonbridge Medical Technology Co Ltd have been 167% over the past three years .